Tirzepatide vs Tesamorelin: Head-to-Head Comparison
Both are FDA-approved peptides affecting metabolic pathways. Tirzepatide (dual GIP/GLP-1 agonist) produces dramatic overall weight loss, while tesamorelin (GHRH analog) specifically reduces visceral fat via GH pathway. Tirzepatide achieves greater total weight loss, but tesamorelin targets visceral adiposity specifically.
Side-by-Side Comparison
| Dimension | Tirzepatide | Tesamorelin |
|---|---|---|
| Evidence Level | Phase III trials (SURMOUNT/SURPASS) | Phase III trials for HIV lipodystrophy |
| FDA Status | FDA-approved for T2D and obesity | FDA-approved for HIV lipodystrophy |
| Mechanism | Dual GIP/GLP-1 receptor agonism | GHRH receptor agonism, GH/IGF-1 elevation |
| Weight Loss Efficacy | ~20-22.5% total body weight loss | Targeted visceral fat reduction (~15-18%) |
| Muscle Impact | Significant lean mass loss (~25-40% of weight lost) | GH pathway may preserve lean mass |
| Side Effects | GI effects (nausea, vomiting, diarrhea) | Arthralgia, edema, injection site reactions |
| Cost | Very high (~$1,000+/month) | Very high (~$800-1,000+/month) |
Peptide Overviews
Tirzepatide
AFDA ApprovedTirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.
Tesamorelin
AFDA ApprovedTesamorelin is a synthetic GHRH analog approved by the FDA as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Tirzepatide vs Tesamorelin: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.